NCT06739720RecruitingPhase 2/3
RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue
A Randomized, Waitlist-controlled Clinical Study on the Efficacy and Safety of Lingzhi-containing Dietary Supplement CP003 on Chronic Fatigue and Post-COVID Fatigue
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are: Does the Lingzhi supplement reduce fatigue symptoms? Is it safe to take? How does it affect the body's immune system and inflammation? The investigators will compare people taking the Lingzhi supplement to those who do not receive any treatment (waitlist group) to see if it works. Participants will: * Take 5 capsules once daily for 6 weeks (or wait to start treatment if in waitlist group) * Visit the clinic 2 times for blood tests (before and after taking the supplement) * Complete questionnaires 3 times about their fatigue and quality of life (4 times participants in the waitlist group)
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- First submitted
- 16 Dec 2024
- Start date
- 2 Jan 2025
- Primary completion date
- 15 Jan 2026
- Lead sponsor
- The University of Hong Kong
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06739720
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 130
- From 2 Jan 2025 to the primary completion date, 15 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have serious medical conditions that might limit their participation in this intervention;
Other
- Have participated in any type of complements or herbal medicine within the past six months;
- Diagnosed with acute inflammation;
- Are pregnant or are planning a pregnancy in the next 3 months.
Who the study is looking for
- Meet the Fukuda diagnostic definition of CFS/ME or have persisting fatigue after the infection of SARS-CoV-2
- Are able to complete a 6-week course of intervention;
- Able to complete the online validated fatigue surveys.
Age in the registry: 40 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Specialist Clinical Centre for Teaching and Research, School of Chinese Medicine, The University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.